R

Relmada Therapeutics

D
RLMD
USD
-0.16
(-4.6784%)
Market Closed
991.00
Volume
-3.09
EPS
-
Div Yield
-1.135889
P/E
98,367,898.52
Market Cap
Today
-4.6784%
1 Week
-6.590%
1 Month
-6.052%
6 Months
-14.883%
12 Months
7.591%
Year To Date
-21.067%
All Time
0%

Title:
Relmada Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment ofdepression and other potential indications.
Do you need help or have a question?